Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Zulfiqar Ali

Internal Medicine Fremont, CA Medical Doctor

NPI 1093740227 CMS profile 50045

1900 Mowry Ave, Ste 105, Fremont, CA 94538

Open in the dashboard

General payments

$10,074

134 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Zulfiqar Ali of Fremont, CA is reported in the CMS Open Payments database as having received $10,074 across 134 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,352 13
2024 General $1,859 21
2023 General $1,318 15
2022 General $1,017 14
2021 General $1,245 19
2020 General $570 9
2019 General $2,714 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Zulfiqar Ali
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Zulfiqar Ali were reported at $1,352. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Zulfiqar Ali Internal Medicine median Middle half National median
2019 $2,714 $159 $48–$570 $163
2020 $570 $119 $33–$402 $114
2021 $1,245 $135 $37–$521 $132
2022 $1,017 $141 $42–$496 $149
2023 $1,318 $149 $45–$519 $160
2024 $1,859 $154 $47–$537 $164
2025 $1,352 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,574 21 payments
  2. Novo Nordisk Inc $1,136 14 payments
  3. Janssen Pharmaceuticals, Inc $787 11 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $631 7 payments
  5. Teva Pharmaceuticals USA, Inc. $600 6 payments
  6. GlaxoSmithKline, LLC. $575 5 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $449 5 payments
  8. Pfizer Inc. $435 14 payments
  9. Amgen Inc. $413 4 payments
  10. Boston Scientific Corporation $305 4 payments
  11. Other $3,167 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,074 134 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $585 10 payments
  2. Ozempic $454 7 payments
  3. LifeVest $449 5 payments
  4. XARELTO $407 6 payments
  5. INVOKANA $380 5 payments
  6. RYBELSUS $343 6 payments
  7. BREZTRI $342 3 payments
  8. ACTHAR $264 3 payments
  9. VYNDAQEL $258 4 payments
  10. JARDIANCE $242 3 payments
  11. Other $5,886 88 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 71 drugs

Part D claims

2,843

Median for Internal Medicine: 777

Drug cost

$141,725

Median for Internal Medicine: $73,373

Branded share of claims

19.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 41 $28,738
Brilinta Ticagrelor Brand 37 $26,796
Trulicity Dulaglutide Brand 23 $21,632
Januvia Sitagliptin Phosphate Brand 16 $15,837
Ozempic Semaglutide Brand 11 $9,061
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 20 $6,276
Advair Hfa Fluticasone Propion/Salmeterol Brand 12 $3,521
Colchicine Generic 14 $2,339
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 25 $2,084
Quetiapine Fumarate Generic 21 $1,762

The 10 drugs with the highest cost, of 71 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$86,401

Medicare's payments for the services billed

Medicare patients

236

Average age 75

Services billed

933

114 women, 122 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 61%
Ischemic heart disease 52%
Arthritis 45%
Heart failure 39%
Chronic kidney disease 33%
COPD 29%
Atrial fibrillation 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UZEDY
  • Teva Pharmaceuticals USA, Inc. $177
$177 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $140
$140 — —
Licart
  • IBSA Pharma Inc. $125
$125 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $124
$124 — —
Nubeqa
  • Bayer HealthCare Pharmaceuticals Inc. $112
$112 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

134 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record